Hugo Wahnish, Non-Executive Director, now owns 0,03 per cent of the company.
A press release sent this morning shows Wahnish purchased 25,000 shares each in Benchmark at a price of US$0.84 per share on June 19th and a further 100,000 Ordinary Shares at a price of US$0.87 per share on June 20th.
Following this transaction, Wahnish’s total beneficial interest in the company is 175,000 shares, representing approximately 0.03 per cent of the xompany’s issued share capital.
Read more: Groundbreaking new sea lice treatment: “All the trials have shown 100 per cent efficacy”
Hugo Wahnish was appointed in 2017 and has over 35 years of experience in the animal health and pharmaceuticals industry, including stints with GlaxoSmithKline and Merck.
